Long-term hypotensive treatment with nitrendipine in mild to moderate essential hypertension: preliminary results of a placebo-controlled study versus atenolol. 1987

C Palombo, and C Marabotti, and A Genovesi-Ebert, and G Giuliano, and S Giaconi, and E Fommei, and L Mezzasalma, and S Ghione
Consiglio Nazionale Delle Ricerche, Institute of Clinical Physiology, Pisa, Italy.

Nitrendipine is a dihydropyridine calcium antagonist suggested to be a new drug for first-line antihypertensive therapy, possibly active in once-daily administration. In the present study the acute and long-term hypotensive effects of nitrendipine have been evaluated in comparison with those of atenolol in a randomized, double-blind, clinical trial. Twenty-four patients have been studied, and the effects of treatment have been evaluated both at rest and during psychological and physiological stresses. Hemodynamic noninvasive parameters have also been obtained, at rest and during mental arithmetic tests, by a continuous-wave Doppler technique. Preliminary results about the first 13 consecutive patients are reported here. Nitrendipine induced a highly significant acute hypotensive effect (2 h after drug administration), whereas no effect was observed for atenolol except for heart rate. During chronic treatment (5 weeks), nitrendipine showed less hypotensive effect than atenolol when BP values 24 h after the last administration were analyzed, but significantly more effect when values obtained 2 h after drug administration were evaluated. These findings confirm that nitrendipine is effective in decreasing blood pressure, but the once-daily administration may not bring about the maximum effect in all patients. Interesting aspects of this drug, which make the clinical use of this compound safe, are represented by apparent lack in tolerance and rebound, and by the moderate increase in cardiac output associated with the treatment.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007036 Hypothermia, Induced Abnormally low BODY TEMPERATURE that is intentionally induced in warm-blooded animals by artificial means. In humans, mild or moderate hypothermia has been used to reduce tissue damages, particularly after cardiac or spinal cord injuries and during subsequent surgeries. Induced Hypothermia,Mild Hypothermia, Induced,Moderate Hypothermia, Induced,Targeted Temperature Management,Therapeutic Hypothermia,Hypothermia, Therapeutic,Induced Mild Hypothermia,Induced Mild Hypothermias,Induced Moderate Hypothermia,Induced Moderate Hypothermias,Mild Hypothermias, Induced,Moderate Hypothermias, Induced,Targeted Temperature Managements
D008297 Male Males
D009568 Nitrendipine A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. Balminil,Bay e 5009,Bayotensin,Baypresol,Baypress,Gericin,Jutapress,Nidrel,Niprina,Nitre AbZ,Nitre-Puren,Nitregamma,Nitren 1A Pharma,Nitren Lich,Nitren acis,Nitrend KSK,Nitrendepat,Nitrendi Biochemie,Nitrendidoc,Nitrendimerck,Nitrendipin AL,Nitrendipin Apogepha,Nitrendipin Atid,Nitrendipin Basics,Nitrendipin Heumann,Nitrendipin Jenapharm,Nitrendipin Lindo,Nitrendipin Stada,Nitrendipin beta,Nitrendipin-ratiopharm,Nitrendipino Bayvit,Nitrendipino Ratiopharm,Nitrensal,Nitrepress,Tensogradal,Trendinol,Vastensium,nitrendipin von ct,nitrendipin-corax,Nitre Puren,NitrePuren,Nitrendipin ratiopharm,Nitrendipinratiopharm,nitrendipin corax,nitrendipincorax
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse

Related Publications

C Palombo, and C Marabotti, and A Genovesi-Ebert, and G Giuliano, and S Giaconi, and E Fommei, and L Mezzasalma, and S Ghione
January 1992, Clinical therapeutics,
C Palombo, and C Marabotti, and A Genovesi-Ebert, and G Giuliano, and S Giaconi, and E Fommei, and L Mezzasalma, and S Ghione
July 1997, Blood pressure,
C Palombo, and C Marabotti, and A Genovesi-Ebert, and G Giuliano, and S Giaconi, and E Fommei, and L Mezzasalma, and S Ghione
April 1990, British journal of clinical pharmacology,
C Palombo, and C Marabotti, and A Genovesi-Ebert, and G Giuliano, and S Giaconi, and E Fommei, and L Mezzasalma, and S Ghione
January 1991, The American journal of cardiology,
C Palombo, and C Marabotti, and A Genovesi-Ebert, and G Giuliano, and S Giaconi, and E Fommei, and L Mezzasalma, and S Ghione
November 1988, Minerva medica,
C Palombo, and C Marabotti, and A Genovesi-Ebert, and G Giuliano, and S Giaconi, and E Fommei, and L Mezzasalma, and S Ghione
January 1990, European journal of clinical pharmacology,
C Palombo, and C Marabotti, and A Genovesi-Ebert, and G Giuliano, and S Giaconi, and E Fommei, and L Mezzasalma, and S Ghione
January 1986, British journal of clinical pharmacology,
C Palombo, and C Marabotti, and A Genovesi-Ebert, and G Giuliano, and S Giaconi, and E Fommei, and L Mezzasalma, and S Ghione
January 1988, Journal of cardiovascular pharmacology,
C Palombo, and C Marabotti, and A Genovesi-Ebert, and G Giuliano, and S Giaconi, and E Fommei, and L Mezzasalma, and S Ghione
October 1990, Journal of human hypertension,
C Palombo, and C Marabotti, and A Genovesi-Ebert, and G Giuliano, and S Giaconi, and E Fommei, and L Mezzasalma, and S Ghione
January 1987, Drug intelligence & clinical pharmacy,
Copied contents to your clipboard!